Advertisement Pharmaceutical Business review - Page 180 of 5271 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 1, 2026

LEO Pharma to acquire gene therapy company Replay

LEO Pharma has signed a definitive agreement for the acquisition of Replay, a gene therapy company that develops treatments for rare genetic dermatological conditions.

LEO Pharma will integrate Replay’s HSV gene therapy design and manufacturing specialists into its dermatology portfolio. Credit: Gorodenkoff / Shutterstock.com.